Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today reported initial data from the first 12 subjects administered PROHEMAA in the Company's ongoing Phase 2 PUMA study and announced that the study's independent Data Monitoring Committee supported continuation of the clinical trial following a second planned interim safety review. These early data showed that subjects administered PROHEMA, the Company's lead ex vivo programmed hematopoietic cellular therapeutic derived from umbilical cord blood, had an improved median time of neutrophil engraftment and an increased incidence of early neutrophil engraftment.
http://ift.tt/1wmkpAI
http://ift.tt/1wmkpAI
No comments:
Post a Comment